<DOC>
	<DOC>NCT00342940</DOC>
	<brief_summary>The present study aims to evaluate safety and immunogenicity of one dose of a commercially available Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, in non-elderly adult and elderly subjects.</brief_summary>
	<brief_title>Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male and female subjects 18 years of age or older any autoimmune disease or other serious acute, chronic or progressive disease hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the vaccine known or suspected (or high risk of developing) impairment/alteration of immune function within the past 7 days any acute disease or infections requiring systemic antibiotic or antiviral therapy history of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>influenza</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>flu</keyword>
	<keyword>vaccination</keyword>
	<keyword>immunogenicity</keyword>
</DOC>